Caredx issues comment letter on draft lcd policy

Brisbane, calif.--(business wire)--caredx, inc. (nasdaq: cdna) – the transplant company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it has submitted its comment letter in response to the draft local coverage determination (lcd) related to molecular testing for solid organ transplant rejection. the comment letter has.
CDNA Ratings Summary
CDNA Quant Ranking